secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2026-05-12T20:05:48+00:00
Accession:  0001683168-26-003722
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q1 2026 revenue $28.04M (+50.8% YoY); pharma up 81.9%, net income $5.44M
--------------------------------------------------------------------------------

- Revenue $28.04M, up 50.8% YoY; pharma $15.68M (+81.9%), plasma $11.75M (+24.9%).
- Net income $5.44M ($0.09 diluted EPS) vs $2.59M ($0.05); adj. EBITDA $10.59M, up 113.4%.
- Operating margin 23.8% vs 13.4% YoY; gross margin 65.0% from 62.9% on pharma mix shift.
- Active patient affordability programs 135 (net +45 in 12 months); plasma centers 573 (net +89).
- Q2 2026 guidance: revenue $26.2M-$26.7M; full-year revenue $106.5M-$110.5M, net income $13M-$16M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/0001683168-26-003722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer